New Pharmaceuticals market report from Global Markets Direct: "Octapharma AG - Product Pipeline Review - 2012"
Boston, MA -- (SBWIRE) -- 01/31/2013 -- Global Market Direct's pharmaceuticals report, "Octapharma AG - Product Pipeline Review - 2012" provides data on the Octapharma AG's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct's proprietary databases, Octapharma AG's corporate website, SEC filings, investor presentations and featured press releases, both from Octapharma AG and industry-specific third party sources, put together by Global Markets Direct's team.
- Octapharma AG - Brief Octapharma AG overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Octapharma AG human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Octapharma AG with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Octapharma AG's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
View Full Report Details and Table of Contents
Reasons to Get this Report
- Evaluate Octapharma AG's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Octapharma AG in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Octapharma AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Octapharma AG.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Octapharma AG and identify potential opportunities in those areas.
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Pharmaceuticals research reports at Fast Market Research
You may also be interested in these related reports:
- Octapharma AG - Product Pipeline Review - H2 2011
- Wilex AG - Product Pipeline Review - 2012
- 4SC AG - Product Pipeline Review - 2012
- Mondobiotech Holding AG - Product Pipeline Review - 2012
- Pieris AG - Product Pipeline Review - 2012
- MediGene AG - Product Pipeline Review - 2012
- Affimed Therapeutics AG - Product Pipeline Review - 2012
- MorphoSys AG - Product Pipeline Review - 2012
- NOXXON Pharma AG - Product Pipeline Review - 2012
- Basilea Pharmaceutica AG - Product Pipeline Review - 2012